[25-NSE] Petros Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Petros Pharmaceuticals, Inc. (PTPI) has had its common stock removed from listing and registration on the Nasdaq Stock Market LLC. Nasdaq filed a Form 25 under Section 12(b) of the Securities Exchange Act of 1934, certifying that it complied with its rules and the requirements of 17 CFR 240.12d2-2(b) to strike this class of securities from listing and/or registration. The filing is signed on behalf of Nasdaq by a hearings advisor, confirming Nasdaq’s action to delist PTPI’s common stock from the exchange.

Positive

• None.

Negative

• PTPI common stock delisted from Nasdaq, removing it from a major national securities exchange and potentially reducing liquidity and visibility.

Insights

Equity markets & listing specialist

Nasdaq has formally delisted PTPI common stock from its exchange.

Petros Pharmaceuticals, Inc. (PTPI) common stock is being removed from listing and registration on the Nasdaq Stock Market LLC, as evidenced by a Form 25 filed under Section 12(b) of the Exchange Act. Nasdaq certifies that it has complied with its own rules and 17 CFR 240.12d2-2(b) to strike this class of securities from the exchange.

Once a Form 25 becomes effective, the security is no longer listed on that national securities exchange and no longer registered under Section 12(b). Trading, if any, typically shifts to over-the-counter venues, where liquidity and price discovery are often more limited than on a major exchange. The practical impact depends on market interest and any alternative trading arrangements after delisting.

The notification is signed by a Nasdaq hearings advisor dated 2025-11-20, indicating that the exchange’s internal process has concluded. Subsequent company disclosures and market data will show where and how PTPI shares trade following the removal from Nasdaq.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-39752

Issuer:	Petros Pharmaceuticals, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	5301 Wisconsin Avenue NW, Suite 570
	Washington	DISTRICT OF COLUMBIA	20015
Telephone number:					732-770-2468

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-11-20	By	Aravind Menon		Hearings Advisor
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Nasdaq announce about Petros Pharmaceuticals (PTPI)?

Nasdaq filed a Form 25Nasdaq Stock Market LLC under Section 12(b) of the Exchange Act.

Which PTPI security is affected by this Form 25 filing?

The filing applies to Petros Pharmaceuticals, Inc. common stock, which is being struck from listing and/or registration on Nasdaq.

Who initiated the delisting of PTPI shares?

The Nasdaq Stock Market LLC initiated the action, certifying under 17 CFR 240.12d2-2(b) that it complied with its rules to strike PTPI’s common stock from listing and/or registration.

Does the Form 25 mean PTPI no longer trades at all?

The Form 25 means PTPI common stock is being removed from Nasdaq listing and Section 12(b) registration. It does not itself state whether or where the stock may trade over the counter.

When was the PTPI Form 25 delisting notice signed?

The notification was signed on 2025-11-20 by a Nasdaq hearings advisor on behalf of the exchange.

What regulatory rule is cited for PTPI’s removal from Nasdaq?

The action cites 17 CFR 240.12d2-2(b), under which the exchange certifies it has complied with its rules to strike the class of securities from listing and/or registration.